Evidence map›Paper›PMID 39112445›Full record

ArticleBlood cancer journal2024

Serum levels of B-cell activating factor are associated with a reduced risk of chronic lymphocytic leukemia.

Eleanor Frost, Jonathan N Hofmann, Wen-Yi Huang, Ashley A Frazer-Abel, Kevin D Deane, Sonja I Berndt

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eleanor FrostDepartment of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-1558-4945
Jonathan N HofmannDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-1043-5812
Wen-Yi HuangDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.ORCID 0000-0002-4440-3368
Ashley A Frazer-AbelDepartment of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Kevin D DeaneDepartment of Medicine, University of Colorado Anschutz Medical Campus, Denver, CO, USA.
Sonja I BerndtDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA. berndts@mail.nih.gov.ORCID 0000-0001-5230-0652

Funding

CANCER RISK IN HUMAN POPULATIONSZ01CP010136 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SILVERMAN, DEBRA · 1997 to 2008
$5.1M
Core 2 - Mucosal Immunobiology Core (MIC)P30AR079369 · NIAMS · UNIVERSITY OF COLORADO DENVER · PI Vernon Michael Holers · 2021 to 2026
$4.7M
Intramural NIH HHS Z01 CP010136NIAMS NIH HHS P30 AR079369
6 · The paper itself

Abstract

impactImmune dysregulation is thought to contribute to chronic lymphocytic leukemia (CLL) risk, but biological mechanisms are unclear. We discovered that increased serum levels of B-cell activating factor (BAFF), an important regulator of B-cell maturation, were associated with a decreased risk of CLL, even >10 years after blood draw. Our findings suggest that BAFF could be a useful biomarker to assess risk among individuals at high risk, such as those with monoclonal b-cell lymphocytosis.

Indexed as

B-Cell Activating FactorLeukemia, Lymphocytic, Chronic, B-CellAgedAged, 80 and overBiomarkers, TumorFemaleHumansMaleMiddle AgedRisk FactorsB-Cell Activating FactorBiomarkers, TumorTNFSF13B protein, human

Identifiers

PMID39112445
PMCPMC11306784

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.